Beta-amyloid

Beta-amyloid

Beta-amyloid (Aβ) is a peptide that is crucially involved in the pathogenesis of Alzheimer's disease. It is derived from the amyloid precursor protein (APP) through enzymatic processes and is known for its tendency to aggregate and form plaques in the brain, which are a hallmark of Alzheimer's disease.

Structure and Formation

Beta-amyloid is a peptide of 36–43 amino acids. It is produced by the sequential cleavage of APP by two enzymes: beta-secretase and gamma-secretase. The cleavage by beta-secretase results in a soluble fragment, while the subsequent cleavage by gamma-secretase releases the beta-amyloid peptide.

Amyloid Precursor Protein (APP)

APP is a transmembrane protein expressed in many tissues, including the brain. It is involved in neuronal growth, survival, and post-injury repair. The exact physiological role of APP and its cleavage products, including beta-amyloid, is not fully understood.

Pathophysiology

In Alzheimer's disease, beta-amyloid peptides aggregate to form oligomers and fibrils, which then deposit as amyloid plaques in the brain. These plaques are thought to disrupt cell-to-cell communication and activate immune responses, leading to inflammation and neuronal death.

Amyloid Cascade Hypothesis

The amyloid cascade hypothesis posits that the accumulation of beta-amyloid is the initial pathological trigger in Alzheimer's disease, leading to tau pathology, neurodegeneration, and cognitive decline. This hypothesis has driven much of the research and therapeutic strategies targeting beta-amyloid.

Detection and Diagnosis

Beta-amyloid can be detected in the brain using positron emission tomography (PET) imaging with specific tracers. Additionally, levels of beta-amyloid in the cerebrospinal fluid (CSF) can be measured as a biomarker for Alzheimer's disease.

Therapeutic Approaches

Several therapeutic strategies have been developed to target beta-amyloid, including:

• Beta-secretase inhibitors: These aim to prevent the initial cleavage of APP, reducing beta-amyloid production.
• Gamma-secretase inhibitors/modulators: These target the second cleavage step, although they have been challenging due to side effects.
• Immunotherapy: This involves using antibodies to clear beta-amyloid from the brain.

Research and Controversies

While beta-amyloid is a central focus in Alzheimer's research, some studies suggest that targeting beta-amyloid alone may not be sufficient to halt disease progression. The role of tau protein, inflammation, and other factors are also being investigated.

See Also

• Alzheimer's disease
• Neurodegenerative diseases
• Tau protein

References

• Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297(5580), 353-356.
• Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews, 81(2), 741-766.